Sana Biotechnology, a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed CAR T therapy.
Sonja Schrepfer, PhD, and Tobias Deuse, PhD, are the UCSF inventors.